Drug reference
tecovirimat
Antiviral
Antiviral
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Not yet extracted
Indications
treatment of smallpoxsevere orthopoxviral infectionssevere manifestations of mpox (especially with severe immunocompromise, prolonged treatment course may be considered)
Dosing
- Adult
- 600 mg orally or 200 mg intravenously every 12 h (with higher or more frequent dosing depending on patient weight) typically for 2 weeks.
Pharmacokinetics
Bioavailability
—
Protein binding
77–82%
Excretion
—
Related guidelines
Other Unclassified drugs
Ask House about tecovirimat
Continue into a citation-backed clinical answer with the drug context already attached.
Textbook-sourced·Sources: Goodman & Gilman 14e, Harrison 22e·Updated: 2026-05-10